Stay updated with breaking news from Deciphera Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $25.59 and last traded at $25.58, with a volume of 366347 shares changing hands. The stock had previously closed at $25.57. Analysts Set New Price Targets A number of […]
Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Free Report) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month […]
Global law firm Greenberg Traurig, LLP represented Japan-based global specialty pharmaceutical company ONO Pharmaceutical Co. in its acquisition of Waltham, Massachusetts-based Deciphera Pharmaceuticals for $25.60 per share in cash, for a total equity value of $2.4 billion.
Guggenheim reaffirmed their neutral rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Other analysts have also recently issued research reports about the company. Jonestrading restated a hold rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a report […]
Jefferies Financial Group restated their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a report released on Monday, Benzinga reports. Jefferies Financial Group currently has a $25.60 price target on the stock, down from their prior price target of $26.00. DCPH has been the topic of several other research reports. Jonestrading […]